Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565887 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
A Phase 3 study, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT03565887 is a Phase 3 study that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 164 participants.
The verdict
NCT03565887, a Phase 3 study, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Interventions
- DRUG RVL-1201
- OTHER Vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03565887
The ClinicalTrials.gov registry entry for NCT03565887 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RVL Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RVL-1201 is the first listed.
NCT03565887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03565887 about?
NCT03565887 is a clinical study titled "Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis". Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
What is the current status of trial NCT03565887?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2018-06-28. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT03565887?
The interventions under investigation include: RVL-1201 (DRUG), Vehicle ophthalmic solution (OTHER).
Who is sponsoring clinical trial NCT03565887?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.